SPG601 granted orphan drug status in EU for fragile X syndrome
SPG601, an oral treatment for fragile X syndrome that's now in clinical testing, has been granted orphan drug status in the European Union.| Fragile X News Today
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to mosliciguat, an investigational inhalation therapy that Pulmovant is developing to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The MHLW gives this designation to experimental medicines intended to treat conditions affecting fewer than 50,000 people in Japan. The goal of […] The post Mosliciguat for PH-ILD granted orphan drug status in Japan appeared first on Pu...| Pulmonary Hypertension News – The Web's Daily Resource for PH News
SPG601, an oral treatment for fragile X syndrome that's now in clinical testing, has been granted orphan drug status in the European Union.| Fragile X News Today
Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
The FDA has granted orphan drug and rare pediatric disease designations to fragile X treatment KER-0193, Kaerus Biosciences said.| Fragile X News Today
An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded orphan drug status.| Pulmonary Fibrosis News
Investigational therapy BPN14770 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of fragile X syndrome.| Fragile X News Today
